



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/681946/2022

European Medicines Agency decision P/0357/2022

of 11 August 2022

on the acceptance of a modification of an agreed paediatric investigation plan for cabozantinib (Cometriq, Cabometyx), (EMA-001143-PIP01-11-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0357/2022

of 11 August 2022

on the acceptance of a modification of an agreed paediatric investigation plan for cabozantinib (Cometriq, Cabometyx), (EMA-001143-PIP01-11-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0128/2012 issued on 4 July 2012, decision P/0134/2016 issued on 20 May 2016, decision P/0331/2019 issued on 11 September 2019, and decision P/0282/2021 issued on 19 July 2021

Having regard to the application submitted by Ipsen Pharma on 25 April 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 22 July 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for cabozantinib (Cometriq, Cabometyx), capsule, hard, tablet, age-appropriate formulation, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Ipsen Pharma, 65 quai George Gorse, 92100 - Boulogne-Billancourt, France.

EMA/PDCO/246645/2022
Amsterdam, 22 July 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001143-PIP01-11-M05

Scope of the application

Active substance(s):

Cabozantinib

Invented name:

Cometriq

Cabometyx

Condition(s):

Treatment of malignant solid tumours

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Capsule, hard

Tablet

Age-appropriate formulation

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Ipsen Pharma

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Ipsen Pharma submitted to the European Medicines Agency on 25 April 2022 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0128/2012 issued on 4 July 2012, decision P/0134/2016 issued on 20 May 2016, decision P/0331/2019 issued on 11 September 2019, and decision P/0282/2021 issued on 19 July 2021.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 23 May 2022.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric Investigation Plan

2.1. Condition

Treatment of malignant solid tumours

2.1.1. Indication(s) targeted by the PIP

- Treatment of refractory malignant solid tumours that are associated with MET, VEGFR, and/or RET pathway activation as a result of mutation, overexpression or amplification.
- Treatment of advanced or metastatic medullary thyroid cancer.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Capsule, hard

Tablet

Age-appropriate formulation

2.1.4. Studies

Area	Description
Quality	Study 1 Development of an age-appropriate formulation.
Non-clinical	Study 2 (XL184-NC-032) Juvenile toxicity and toxicokinetic study. Study 3 Comprehensive paediatric non-clinical efficacy testing program.
Clinical	Study 4 (XL184-011) Open-label trial to evaluate toxicity, tolerability, pharmacokinetics and pharmacodynamics of cabozantinib in children from 2 years to less than 18 years of age with refractory or relapsed malignant solid tumours. Study 5 (XL184-005) Trial to evaluate relative bioavailability (in adults).

	Study 7 (XL189) Open-label trial to evaluate the safety and activity of cabozantinib in children from 2 years to less than 18 years of age (and young adults) with a relapsed or refractory solid malignant tumour. Study 6 (XL184-208) Randomised, double-blind, controlled, parallel-group safety and efficacy clinical trial of cabozantinib in patients aged from birth to less than 18 years with a malignant solid tumour(s) determined based on results of studies 3 and 4.
--	--

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By January 2024
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of renal cell carcinoma

Authorised indication(s):

- Treatment of advanced renal cell carcinoma - as first-line treatment of adult patients with intermediate or poor risk - in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.
- In combination with nivolumab, for first-line treatment of advanced renal cell carcinoma in adults.

2. Treatment of hepatocellular carcinoma

Authorised indication(s):

- Treatment of hepatocellular carcinoma in adults who have previously been treated with sorafenib.

3. Treatment of medullary thyroid carcinoma

Authorised indication(s):

- Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.

4. Treatment of Differentiated thyroid carcinoma

Authorised indication(s):

- Treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.

Authorised pharmaceutical form(s):

Capsule, hard

Tablet

Authorised route(s) of administration:

Oral use